Table 2.
GRADE evidence profile.
| Outcomes | RCTs | Quality assessment | No. of patients | Effect size | Quality | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Risk of bias | Inconsistency | Indirectness | Imprecision | Reporting bias | T | C | ||||
| The short-term efficacy of solid tumors | 10 | seriousa | No | No | No | No | 159/372 | 112/364 | OR=1.74 (1.27 to 2.39) | Low |
| QOL | 11 | No | No | No | No | No | 178/374 | 94/367 | OR=3.75(2.58 to 5.44) | Moderate |
| Clinical Symptoms | 4 | No | seriousc | No | seriousb | No | 96/119 | 66/116 | MD=3.69 (1.43 to 9.49) | very low |
| Depression | 3 | No | No | No | seriousb | No | 103 | 103 | OR=-12.96 (-16.09 to -9.83) | Low |
| Leukocyte | 8 | No | No | No | No | No | 106/250 | 148/245 | OR=0.32 (0.20 to 0.50) | Moderate |
| Platelets | 4 | No | No | No | seriousb | No | 63/115 | 84/112 | OR=0.37 (0.20 to 0.67) | Low |
| Nausea and Vomiting | 8 | No | No | No | No | No | 93/258 | 132/254 | OR=0.26 (0.15 to 0.44) | Moderate |
| The Damage to Liver and Kidney | 4 | No | No | No | seriousb | No | 20/112 | 28/112 | OR=0.59 (0.29 to 1.21) | Low |
| Cardiotoxicity | 5 | No | No | No | No | No | 7/195 | 34/193 | OR=0.16 (0.07 to 0.36) | Moderate |
| Survival Rate | 3 | No | No | No | No | No | 116/128 | 101/124 | OR=2.19 (1.03 to 4.66) | Moderate |
a
Most trials had unclear risk, and with high risk, but the result had good robustness. The evidence was rated down by only one level.
b
The sample size was small and the confidence interval was wide. Therefore, the evidence was rated down by one level.
c
Heterogeneity presented in them.Therefore, the evidence was rated down by one level.